Downregulation of hepatic cytochrome P450 in chronic renal failure

Journal of the American Society of Nephrology

Volumn 12, Issue 2, 2001, Pages 326-332

  Leblond, F ^a   Guevin C ^a   Demers, C ^a   Pellerin, I ^a   Gascon Barre M ^a   Pichette, V ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C11; CYTOCHROME P450 2C6; CYTOCHROME P450 2D; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; CYTOCHROME P450 ISOENZYME; DEXAMETHASONE; ERYTHROMYCIN; MESSENGER RNA; PHENOBARBITAL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE CLEARANCE; DEMETHYLATION; DISEASE ASSOCIATION; DOWN REGULATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME REGULATION; GENE EXPRESSION; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0035146107     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Drug administration in patients with renal insufficiency. Minimizing renal and extrarenal toxicity
2. Principles of drug administration in renal insufficiency
3. The effect of renal failure on hepatic drug clearance
4. Drug dosing in renal insufficiency
5. Renal disease and drug metabolism: An overview
6. Oxidative drug metabolism in liver microsomes from uremic rats
7. Hepatic oxidative drug metabolism in rats with experimental renal failure
8. Enzyme induction in the uremic liver
9. Hepatic drug metabolism in rats with experimental chronic renal failure
10. The human hepatic cytochromes P450 involved in drug metabolism
11. Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (CRF) rats by partial nephrectomy
12. Rat and human liver cytochrome P450: Substrate and inhibitor specificities and functional markers
13. 2+-sedimented microsomes from rat liver
14. Protein measurement with the folin phenol reagent
15. The carbon monoxide-binding pigment of liver microsomes
16. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
17. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets
18. 3-Methylcholanthrene and pyridine effects on CYP1A1 and CYP1A2 expression in rat renal tissue
19. Downregulation of male-specific cytochrome P450s 2C11 and 3A2 in bile duct-ligated male rats: Importance to reduced hepatic content of cytochrome P450 in cholestasis
20. Pregnenolone 16 alpha-carbonitrile-inducible P-450 gene family: Gene conversion and differential regulation
21. Structure of a gene and cDNA of a major constitutive form of testosterone 6 beta-hydroxylase (P450/6 beta A) encoding CYP3A2: Comparison of the cDNA with P450PCN2
22. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis
23. The calorimetric estimation of formaldehyde by means of the Hantzsh reaction
24. Drug prescribing for patients with changing renal function
25. Effects of caloric restriction on rodent drug and carcinogen metabolizing enzymes: Implications for mutagenesis and cancer
26. Influence of age and caloric restriction on expression of hepatic genes for xenobiotic and oxygen metabolizing enzymes in the mouse
27. Abnormalities in hepatic lipase in chronic renal failure: Role of excess parathyroid hormone
28. Impaired actions of insulin-like growth factor 1 on protein synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect
29. Chronic renal failure is a state of cellular calcium toxicity
30. Chronic renal failure increases cytosolic Ca2+ of hepatocytes
31. Calcium regulates human CYP11B2 transcription
32. 2+ entry in human and bovine endothelial cells
33. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: Comparison of sparteine and dextromethorphan
34. Pharmacokinetics of cefmenoxime in patients with impaired renal function and in those undergoing hemodialysis